Literature DB >> 7103459

Rifampin blood and tissue levels in patients undergoing cardiac valve surgery.

G L Archer, B C Armstrong, B J Kline.   

Abstract

Single 600-mg capsules of rifampin were given orally to 26 patients as prophylaxis during cardiac valve replacement. Antibiotic concentrations were measured in blood (serum or plasma) and tissue (excised cardiac valve). The serum or plasma levels of rifampin in 18 patients who ingested this drug 2 h before they received preoperative opiates and anticholinergics intramuscularly were not significantly different from the levels in four normal volunteers who received the drug. These levels were 15.9 +/- 6.5 micrograms/ml (mean +/- standard deviation) 2 h after drug administration, 7.1 +/- 4.3 micrograms/ml 8 h after drug administration and 2 h after a mean of 1.4 h on cardiopulmonary bypass, and 1.6 +/- 1.6 micrograms/ml 24 h after drug ingestion. The valve tissue level was 3.8 +/- 2.7 micrograms/g (mean +/- standard deviation; n = 10). This value was 65% of the simultaneous serum and plasma levels and 31% of the peak serum and plasma levels. Eight patients who were given rifampin at the same time that they received other preoperative medications had significantly lower blood levels than the 18 patients who received rifampin 2 h earlier (P less than 0.001). No rifampin was detected in valves from seven of these patients. Decreased rifampin absorption due to simultaneous administration with opiates and anticholinergics was the probable reason for the low plasma and serum levels observed. These data suggest that, if properly dosed, rifampin administered orally gives high blood and valve tissue levels, which are affected minimally by cardiopulmonary bypass in patients undergoing cardiac valve surgery.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7103459      PMCID: PMC182014          DOI: 10.1128/AAC.21.5.800

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Belladonna alkaloid-sedative mixture; effects on gastric acidity and motility.

Authors:  F STEIGMANN; L KAMINSKI
Journal:  Am J Dig Dis       Date:  1956-04

Review 2.  Gastrointestinal pharmacology.

Authors:  T F Burks
Journal:  Annu Rev Pharmacol Toxicol       Date:  1976       Impact factor: 13.820

3.  Quantitative assay of rifampicin and three of its metabolites in human plasma, urine and saliva by high-performance liquid chromatography.

Authors:  J B Lecaillon; N Febvre; J P Metayer; C Souppart
Journal:  J Chromatogr       Date:  1978-03-01

Review 4.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

5.  Pharmacokinetic interactions with rifampicin.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

6.  Antibiotic therapy of experimental Staphylococcus epidermidis endocarditis.

Authors:  G J Vazquez; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

7.  Antimicrobial susceptibility and selection of resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices.

Authors:  G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

8.  Antibiotic prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.

Authors:  G L Archer; G J Vazquez; J L Johnston
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

9.  Cefamandole kinetics during cardiopulmonary bypass.

Authors:  R E Polk; G L Archer; R Lower
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

10.  Antibiotic levels in infected and sterile subcutaneous abscesses in mice.

Authors:  K A Joiner; B R Lowe; J L Dzink; J G Bartlett
Journal:  J Infect Dis       Date:  1981-03       Impact factor: 5.226

  10 in total
  4 in total

1.  A physiologically based pharmacokinetic model of rifampin in mice.

Authors:  Michael A Lyons; Brad Reisfeld; Raymond S H Yang; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

2.  Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection.

Authors:  Alexandra I Stavrakis; Jared A Niska; Jonathan H Shahbazian; Amanda H Loftin; Romela Irene Ramos; Fabrizio Billi; Kevin P Francis; Michael Otto; Nicholas M Bernthal; Daniel Z Uslan; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

Review 3.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 4.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.